drugset / Trial / NCT02283788

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

NCT02283788

Phase 1 Completed 67 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women

Timeline

Start
2007-03
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 1200 mg
Subject Eslicarbazepine acetate Unknown 2400 mg
Subject Moxifloxacin Small molecule 400 mg

Indications